Ascendis Pharma (ASND) Tops Q1 EPS by 31c

Ascendis Pharma (NASDAQ: ASND) reported Q1 EPS of (EUR0.06), EUR0.31 better than the analyst estimate of (EUR0.37). Revenue for the quarter came in at EUR2.1 million versus the consensus estimate of EUR2.24 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• The free USDA tool that tracks egg prices at $0.62/dozen before your data vendor does
• Sypris Solutions (SYPR) Reports Q2 Loss of $0.14